米力农在治疗脓毒症伴心衰中的效果评价

Evaluation of Milinone in the Treatment of Sepsis with Heart Failure

目的研究了米力农在脓毒症伴心衰患者中的治疗效果。方法方便选取2016年5月-2019年4月该院收治的脓毒症患者60例,按照随机数字法分为对照组和观察组,各30例。对照组进行常规治疗,观察组在对照组的基础上使用米力农注射液。对两组患者治疗前后的心功能和NT-ProBNP水平变化进行比较,比较两组患者治疗后的APACHEⅡ评分、心功能改善情况、住院时间以及机械通气时间,比较两组患者治疗前后心肌酶及c TnⅠ水平的变化。结果治疗后,观察组心率(68.52±7.37)次/min vs (78.39±8.26)次/min、NT-ProBNP(1 316.26±175.53)pg/L vs (2231.54±184.15)pg/L水平明显低于对照组,LVEF水平明显高于对照组(54.82±10.13)%vs (49.12±9.34)%(t=3.544、6.231、2.941,P<0.05);APACHEⅡ评分明显低于对照组(9.87±2.82)分vs (14.36±3.15)分,住院时间(15.92±2.36)d vs(23.16±4.15)d、机械通气时间(2.23±1.12)d vs (4.51±1.42)d明显短于对照组,心功能改善率明显高于对照组(96.67%vs 70.00%)(t=3.819、3.011、4.184;χ~2=7.680,P<0.05);血清CK (89.56±17.49)IU/L vs (101.24±19.83)IU/L、cTnⅠ(0.74±0.22)mg/L vs (1.86±0.31)mg/L和CK-MB (34.62±6.51)IU/L vs (42.19±7.89)IU/L水平均明显低于对照组(t=2.996、5.103、4.212,P<0.05)。结论在常规治疗的基础上,使用米力农,能够明显降低脓毒症伴心衰患者的住院时间,改善心功能,减轻患者的心肌损伤程度。

Objective To study the therapeutic effect of milrinone in patients with sepsis and heart failure. Methods Convenient select 60 patients with sepsis treated in the hospital from May 2016 to April 2019 were enrolled, and they were divided into control group and observation group according to random number method, 30 cases each. The control group received conventional treatment, and the observation group used Milinone injection on the basis of the control group. The changes in cardiac function and NT-ProBNP levels before and after treatment were compared between the two groups of patients. The APACHE Ⅱ score, cardiac function improvement, hospital stay, and mechanical ventilation time were compared between the two groups of patients. Myocardial enzymes and cTnⅠ changes in level were compared before and after treatment. Results After treatment, the heart rate(68.52 ±7.37)tmes/min vs(78.39 ±8.26)tmes/min NT-ProBNP(1316.26±175.53)pg/L vs(2 231.54±184.15)pg/L were significantly lower in the observation group than in the control group,and the LVEF level was significantly higher than that in the control group(54.82±10.13)% vs(49.12±9.34)%(t=3.544, 6.231,2.941, P<0.05);APACHEⅡ score was significantly lower than the control group(9.87±2.82)points vs(14.36±3.15)points hospital stay(15.92 ±2.36)d vs(23.16 ±4.15)d, and mechanical ventilation time(2.23 ±1.12)d vs(4.51 ±1.42)d was significantly shorter than the control group, and cardiac function improvement was significantly higher than the control group(96.67% vs 70.00%)(t=3.819, 3.011, 4.184, χ~2=7.680, P<0.05);serum CK(89.56±17.49)IU/L vs (101.24±19.83)IU/L,c TnⅠ(0.74±0.22)mg/L vs(1.86±0.31)mg/L and CK-MB(34.62±6.51)IU/L vs(42.19±7.89)IU/L were significantly lower than those in the control group(t =2.996,5.103,4.212, P <0.05). Conclusion On the basis of conventional treatment, using milrinone can significantly reduce the length of hospital stay of patients with sepsis and heart failure, improve cardiac function, and reduce the degree of myocardial damage in patients.